Hairless albino mice with squamous cell carcinoma were exposed to a mixture of 2.5 percent oxygen and 97.5 percent hydrogen at a total pressure of 8 atmospheres for periods up to 2 weeks in order to see if a free radical decay catalyzer, such as hydrogen, would cause a regression of the skin tumors. Marked aggression of the tumors was found, leading to the possibility that hyperbaric hydrogen therapy might also prove to be of significance in the treatment of other types of cancer.
definitive chemotherapy and/or radiation. There were not significant differences between groups. In patients with esophageal adenocarcinoma the analysis of overall survival did not reach statistical significance. The median overall survival of patients with esophageal squamous cell cancer treated with Nimotuzumab + Radiotherapy + Chemotherapy was 14.1 (7.4-20.6) versus 11.3 (5.1-17.6) in patients treated with chemoradiotherapy only (Log-Rank 0.039). ConClusions: This observational design provides real world evidence that corroborate the survival results obtained in clinical trials with Nimotuzumab in esophageal squamous cell cancer. The combination of Nimotuzumab and chemoradiation in this location is confirmed as a promising regimen in patients with esophageal squamous cell cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.